{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:37:08Z","timestamp":1774543028125,"version":"3.50.1"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Eng Ethics"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s11948-018-0041-5","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T07:41:04Z","timestamp":1525246864000},"page":"1167-1192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Medicines Information and the Regulation of the Promotion of Pharmaceuticals"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4967-1916","authenticated-orcid":false,"given":"Teresa","family":"Leonardo Alves","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5120-8029","authenticated-orcid":false,"given":"Joel","family":"Lexchin","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8671-915X","authenticated-orcid":false,"given":"Barbara","family":"Mintzes","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,5,2]]},"reference":[{"key":"41_CR1","first-page":"2","volume":"2","author":"K Alam","year":"2009","unstructured":"Alam, K., Shah, A., Ojha, P., Palaien, S., & Shankar, P. (2009). Evalaution of drug promotional materials in a hospital setting in Nepal. Southern Med Review,\n                           2, 2\u20136.","journal-title":"Southern Med Review"},{"key":"41_CR2","unstructured":"Almashat, S., Wolfe, S., & Carome, M. (2016). Twenty-five years of pharmaceutical industry criminal and civil penalties: 1991 through 2015. Washington, DC: Public Citizen."},{"key":"41_CR3","unstructured":"American Medical Students Association (2009). PharmFree Scorecard. \n                    http:\/\/www.amsascorecard.org\/institutions\/90\n                    \n                  . Accessed May 18, 2017."},{"key":"41_CR4","unstructured":"Australian Competition and Consumer Commission (2006). Tougher reporting under revised drug companies code. Canberra: Australian Competition and Consumer Commission."},{"key":"41_CR5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1046\/j.1525-1497.1999.01049.x","volume":"14","author":"R Bell","year":"1999","unstructured":"Bell, R., Kravitz, R., & Wilkes, M. (1999). Direct-to-consumer prescription drug advertising and the public. Journal of General Internal Medicine,\n                           14, 651\u2013657.","journal-title":"Journal of General Internal Medicine"},{"key":"41_CR6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2165\/00019053-200725060-00006","volume":"25","author":"A Block","year":"2007","unstructured":"Block, A. (2007). Costs and benefits of direct-to-consumer advertising: the case of depression. PharmacoEconomics,\n                           25, 511\u2013521.","journal-title":"PharmacoEconomics"},{"key":"41_CR7","doi-asserted-by":"publisher","first-page":"e0175493","DOI":"10.1371\/journal.pone.0175493","volume":"12","author":"H Brax","year":"2017","unstructured":"Brax, H., Fadlallah, R., Al-Khaled, L., Kahale, L., Nas, H., El-Jardali, F., et al. (2017). Association between physicians\u2019 interaction with pharmaceutical companies and their clinical practices: a systematic review and meta-analysis. PLoS One,\n                           12, e0175493.","journal-title":"PLoS One"},{"key":"41_CR200","unstructured":"Bruce, F. (2008). Brazil to improve advertising regulations. SCRIP."},{"issue":"2","key":"41_CR9","first-page":"4","volume":"9","author":"J Buckley","year":"2004","unstructured":"Buckley, J. (2004). Pharmaceutical marketing\u2014Time for a change. Electronic Journal of Business Ethics and Organizational Studies,\n                           9(2), 4\u201311.","journal-title":"Electronic Journal of Business Ethics and Organizational Studies"},{"key":"41_CR10","unstructured":"Bulk, B. (2016). Up up and away: 2015 pharma ad spending ties decade-old record. \n                    http:\/\/www.fiercepharma.com\/marketing\/up-up-and-away-2015-pharma-ad-spending-ties-decade-old-record\n                    \n                  . Accessed May 15, 2017."},{"key":"41_CR11","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1056\/NEJMsa064508","volume":"356","author":"E Campbell","year":"2007","unstructured":"Campbell, E., Gruen, R., Mountford, J., Miller, L., Cleary, P., & Blumenthal, D. (2007). A national survey of physician-industry relationships. New England Journal of Medicine,\n                           356, 1742\u20131750.","journal-title":"New England Journal of Medicine"},{"key":"41_CR12","unstructured":"Canadian pharmaceutical industry review 2015 (2016). \n                    http:\/\/imsbrogancapabilities.com\/YIR_2015_FINAL\n                    \n                  . Accessed January 31, 2017."},{"key":"41_CR13","unstructured":"Carlat, D. Dr. drug rep. (2007, November 25). New York Times."},{"key":"41_CR14","volume-title":"The 2008 EU industrial R&D investment scoreboard","author":"European Commission","year":"2008","unstructured":"Commission, European. (2008). The 2008 EU industrial R&D investment scoreboard. Brussels: European Commission."},{"key":"41_CR15","unstructured":"Comunica\u00e7\u00f5es ao INFARMED, I.P., no \u00e2mbito da Transpar\u00eancia e Publicidade de acordo com o Artigo 159.\u00ba do Decreto-Lei n.\u00ba 176\/2006, de 30\/08 (Medicamentos) e, com o artigo 52.\u00ba do Decreto-Lei n.\u00ba 145\/2009, de 17\/06 (Dispositivos M\u00e9dicos) (2009). \n                    https:\/\/placotrans.infarmed.pt\/index.aspx\n                    \n                  . Accessed May 28 2017."},{"key":"41_CR16","unstructured":"Consumers International. (2006). Branding the cure: a consumer perspective on corporate social responsibility, drug promotion and the pharmaceutical industry in Europe. London."},{"key":"41_CR17","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1001\/jamainternmed.2016.2765","volume":"176","author":"C DeJong","year":"2016","unstructured":"DeJong, C., Aguilar, T., Tseng, C.-W., Lin, G., Boscardin, W., & Dudley, R. (2016). Pharmaceutical industry-sponsored meals and physician prescribing patterns for medicare beneficiaries. JAMA Internal Medicine,\n                           176, 1114\u20131122.","journal-title":"JAMA Internal Medicine"},{"key":"41_CR18","unstructured":"Elliott, C. (2010). The secret lives of big pharma\u2019s \u2018thought leaders\u2019. \n                    http:\/\/chronicle.com\/article\/The-Secret-Lives-of-Big\/124335\/\n                    \n                  . Accessed April 13, 2015."},{"key":"41_CR20","unstructured":"European Federation of Pharmaceutical Industries and Associations (2011). EFPIA code of practice on relationships between the pharmaceutical industry and patient organisations. \n                    http:\/\/transparency.efpia.eu\/uploads\/Modules\/Documents\/code_po2011.pdf\n                    \n                  . Accessed May 18, 2017."},{"key":"41_CR21","unstructured":"European Federation of Pharmaceutical Industries and Associations. (2007). EFPIA Code on the promotion of prescription-only medicines to, and interactions with, healthcare professionals."},{"key":"41_CR22","unstructured":"Evans, D. (2009, December). Big pharma\u2019s crime spree. Bloomberg Markets, 72\u201386."},{"key":"41_CR23","first-page":"102","volume":"127","author":"S Every-Palmer","year":"2014","unstructured":"Every-Palmer, S., Duggal, R., & Menkes, D. B. (2014). Direct-to-consumer advertising of prescription medication in New Zealand. New Zealand Medical Journal,\n                           127, 102\u2013110.","journal-title":"New Zealand Medical Journal"},{"key":"41_CR24","doi-asserted-by":"publisher","first-page":"e016701","DOI":"10.1136\/bmjopen-2017-016701","volume":"7","author":"A Fabbri","year":"2017","unstructured":"Fabbri, A., Grundy, Q., Mintzes, B., Swandari, S., Moynihan, R., Walkom, E., et al. (2017). A cross-sectional analysis of pharmaceutical industry-funded events for health professioinals in Australia. British Medical Journal Open,\n                           7, e016701. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2017-016701\n                    \n                  .","journal-title":"British Medical Journal Open"},{"key":"41_CR25","unstructured":"Fact or fiction? What healthcare professionals need to know about pharmaceutical marketing in the European Union (2016). Amsterdam: Health Action International."},{"key":"41_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11606-013-2604-0","volume":"29","author":"AE Faerber","year":"2013","unstructured":"Faerber, A. E., & Kreling, D. H. (2013). Content analysis of false and misleading claims in television advertising for prescription and nonprescription drugs. Journal of General Internal Medicine,\n                           29, 110\u2013118.","journal-title":"Journal of General Internal Medicine"},{"key":"41_CR27","volume-title":"Prescription drugs and mass media advertising","author":"S Findlay","year":"2000","unstructured":"Findlay, S. (2000). Prescription drugs and mass media advertising. Washington, DC: National Institute for Health Care Management."},{"key":"41_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1747-5341-9-7","volume":"9","author":"J Francer","year":"2014","unstructured":"Francer, J., Izquierdo, J., Music, T., Narsai, K., Nikidis, C., Simmonds, H., et al. (2014). Ethical pharmaceutical promotion and communications worldwide: Codes and regulations. Philosophy, Ethics, and Humanities in Medicine,\n                           9, 7.","journal-title":"Philosophy, Ethics, and Humanities in Medicine"},{"key":"41_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2105\/AJPH.2008.153767","volume":"100","author":"D Frosch","year":"2010","unstructured":"Frosch, D., Grande, D., Tam, D., & Kravitz, R. (2010). A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising. American Journal of Public Health,\n                           100, 24\u201332.","journal-title":"American Journal of Public Health"},{"key":"41_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1370\/afm.611","volume":"5","author":"D Frosch","year":"2007","unstructured":"Frosch, D., Krueger, P., Hornik, R., Cronholm, P., & Barg, F. (2007). Creating demand for prescription drugs: a content analysis of television direct-to-consumer advertising. Annals of Family Medicine,\n                           5, 6\u201313.","journal-title":"Annals of Family Medicine"},{"key":"41_CR31","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1525-1497.2005.05857.x","volume":"20","author":"A Fugh-Berman","year":"2005","unstructured":"Fugh-Berman, A. (2005). The corporate coauthor. Journal of General Internal Medicine,\n                           20, 546\u2013548.","journal-title":"Journal of General Internal Medicine"},{"key":"41_CR32","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1371\/journal.pmed.0050210","volume":"5","author":"A Fugh-Berman","year":"2008","unstructured":"Fugh-Berman, A. (2008). Off-label promotion, on target sales. PLoS Medicine,\n                           5, e210.","journal-title":"PLoS Medicine"},{"key":"41_CR33","volume-title":"The nature of capital in the knowledge-based economy: The case of the global pharmaceutical industry","author":"M-A Gagnon","year":"2009","unstructured":"Gagnon, M.-A. (2009). The nature of capital in the knowledge-based economy: The case of the global pharmaceutical industry. Toronto: York University."},{"issue":"1","key":"41_CR34","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1371\/journal.pmed.0050001","volume":"5","author":"M-A Gagnon","year":"2008","unstructured":"Gagnon, M.-A., & Lexchin, J. (2008). The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States. PLoS Medicine,\n                           5(1), e1.","journal-title":"PLoS Medicine"},{"key":"41_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4103\/2279-042X.185711","volume":"5","author":"P Ganashree","year":"2016","unstructured":"Ganashree, P., Bhuvana, K., & Sarala, N. (2016). Critical review of drug promotional literature using the World Health Organization guidelines. Journal of Research in Pharmacy Practice,\n                           5, 162\u2013165.","journal-title":"Journal of Research in Pharmacy Practice"},{"key":"41_CR36","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(05)17864-7","volume":"365","author":"D Graham","year":"2005","unstructured":"Graham, D., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., et al. (2005). Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet,\n                           365, 475\u2013481.","journal-title":"Lancet"},{"key":"41_CR37","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/archinternmed.2009.64","volume":"169","author":"D Grande","year":"2009","unstructured":"Grande, D., Frosch, D., Perkins, A., & Kahn, B. (2009). Effect of exposure to small pharmaceutical promotional items on treatment preferences. Archives of Internal Medicine,\n                           169, 887\u2013893.","journal-title":"Archives of Internal Medicine"},{"key":"41_CR38","doi-asserted-by":"publisher","first-page":"j1855","DOI":"10.1136\/bmj.j1855","volume":"357","author":"T Greenway","year":"2017","unstructured":"Greenway, T., & Ross, J. (2017). US drug marketing: how does promotion correspond with health value? BMJ,\n                           357, j1855.","journal-title":"BMJ"},{"key":"41_CR39","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2190\/GYW9-XUMQ-M3K2-T31C","volume":"30","author":"D Guldal","year":"2000","unstructured":"Guldal, D., & Semin, S. (2000). The influences of drug companies\u2019 advertising programs on physicians. International Journal of Health Services,\n                           30, 585\u2013595.","journal-title":"International Journal of Health Services"},{"key":"41_CR40","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.clinthera.2005.09.006","volume":"27","author":"R Hansen","year":"2005","unstructured":"Hansen, R., Shaheen, N., & Schommer, J. (2005). One proton pump inhibitor to another: the effect of direct-to-consumer advertising. Clinical Therapeutics,\n                           27, 1478\u20131487.","journal-title":"Clinical Therapeutics"},{"key":"41_CR41","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2923.1977.tb00595.x","volume":"11","author":"E Hemminki","year":"1977","unstructured":"Hemminki, E. (1977). Content analysis of drug-detailing by pharmaceutical representatives. Medical Education,\n                           11, 210\u2013215.","journal-title":"Medical Education"},{"key":"41_CR42","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/002204268801800210","volume":"18","author":"E Hemminki","year":"1988","unstructured":"Hemminki, E. (1988). Commercial information on drugs: confusing the physician? Journal of Drug Issues,\n                           18, 245\u2013257.","journal-title":"Journal of Drug Issues"},{"key":"41_CR43","unstructured":"Hensley, S., & Martinez, B. (2005, July 15). New treatment: to sell their drugs, companies increasingly rely on doctors\u2014For $750 and up, physicians tell peers about products; talks called educational\u2014Dr. Pitt\u2019s busy speaking tour. Wall Street Journal, p. A1."},{"key":"41_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2190\/1AK2-X8CX-QQ9E-F6ED","volume":"23","author":"A Herxheimer","year":"1993","unstructured":"Herxheimer, A., Lundborg, C., & Westerholm, B. (1993). Advertisements for medicines in leading medical journals in 18 countries: a 12-month survey of information content and standards. International Journal of Health Services,\n                           23, 161\u2013172.","journal-title":"International Journal of Health Services"},{"key":"41_CR45","first-page":"553","volume":"153","author":"B Hodges","year":"1995","unstructured":"Hodges, B. (1995). Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. CMAJ,\n                           153, 553\u2013559.","journal-title":"CMAJ"},{"key":"41_CR46","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1509\/jppm.21.2.202.17586","volume":"21","author":"J Hoek","year":"2002","unstructured":"Hoek, J. (2002). Direct-to-consumer advertising down under: an alternative perspective and regulatory framework. Journal of Public Policy & Marketing,\n                           21, 202\u2013212.","journal-title":"Journal of Public Policy & Marketing"},{"key":"41_CR47","unstructured":"House of Commons Standing Committee on Health. (2004). Opening the medicine cabinet: first report on health aspects of prescription drugs. Ottawa."},{"key":"41_CR48","unstructured":"International Federation of Pharmaceutical Manufacturers and Associations. (2007). Preamble to the IFPMA marketing code: 2006 revision. Geneva."},{"key":"41_CR130","unstructured":"International Federation of Pharmaceutical Manufacturers and Associations. (2012). IFPMA code of practice. Geneva."},{"key":"41_CR49","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/pubmed\/fdm024","volume":"29","author":"M Islam","year":"2007","unstructured":"Islam, M., & Farah, S. (2007). Misleading promotion of drugs in Bangladesh: evidence from drug promotional brochures distributed to general practitioners by the pharmaceutical companies. Journal of Public Health,\n                           29, 212\u2013213.","journal-title":"Journal of Public Health"},{"key":"41_CR50","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2165\/00019053-200826070-00003","volume":"26","author":"J Jureidini","year":"2008","unstructured":"Jureidini, J., Mintzes, B., & Raven, M. (2008). Does direct-to-consumer advertising of antidepressants lead to a net social benefit? PharmacoEconomics,\n                           26, 557\u2013566.","journal-title":"PharmacoEconomics"},{"key":"41_CR51","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1162\/15265160360706552","volume":"3","author":"D Katz","year":"2003","unstructured":"Katz, D., Caplan, A., & Merz, J. (2003). All gifts large and small. American Journal of Bioethics,\n                           3, 39\u201346.","journal-title":"American Journal of Bioethics"},{"key":"41_CR52","doi-asserted-by":"publisher","first-page":"813","DOI":"10.15171\/ijhpm.2015.157","volume":"4","author":"H Kim","year":"2015","unstructured":"Kim, H. (2015). Trouble spots in online direct-to-consumer prescription drug promotion: a content analysis of FDA warning letters. International Journal of Health Policy and Management,\n                           4, 813\u2013821.","journal-title":"International Journal of Health Policy and Management"},{"key":"41_CR53","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4038\/cmj.v61i4.8394","volume":"61","author":"M Kommalage","year":"2016","unstructured":"Kommalage, M., Navanarasie, D., & Basnayake, S. (2016). Scientific research-based evidence used in drug promotion material distributed in Sri Lanka. Ceylon Medical Journal,\n                           61, 199.","journal-title":"Ceylon Medical Journal"},{"key":"41_CR54","doi-asserted-by":"publisher","first-page":"e23336","DOI":"10.1371\/journal.pone.0023336","volume":"6","author":"D Korenstein","year":"2011","unstructured":"Korenstein, D., Keyhani, S., Mendelson, A., & Ross, J. (2011). Adherence of pharmaceutical advertisements in medical journals to FDA guidelines and content for safe prescribing. PLoS One,\n                           6, e23336.","journal-title":"PLoS One"},{"key":"41_CR55","doi-asserted-by":"publisher","first-page":"e55504","DOI":"10.1371\/journal.pone.0055504","volume":"8","author":"R Kornfield","year":"2013","unstructured":"Kornfield, R., Donohue, J., Berndt, E., & Alexander, G. (2013). Promotion of prescription drugs to consumers and providers, 2001\u20132010. PLoS One,\n                           8, e55504.","journal-title":"PLoS One"},{"key":"41_CR56","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1001\/jama.293.16.1995","volume":"293","author":"R Kravitz","year":"2005","unstructured":"Kravitz, R., Epstein, R., Feldman, M., Franz, C., Azari, R., Wilkes, M., et al. (2005). Influence of patients\u2019 requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA,\n                           293, 1995\u20132002.","journal-title":"JAMA"},{"key":"41_CR57","doi-asserted-by":"publisher","first-page":"a1055","DOI":"10.1136\/bmj.a1055","volume":"337","author":"M Law","year":"2008","unstructured":"Law, M., & Soumerai, S. (2008). Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: Controlled longitudinal study. BMJ,\n                           337, a1055.","journal-title":"BMJ"},{"key":"41_CR58","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/jama.2016.21041","volume":"317","author":"J Layton","year":"2017","unstructured":"Layton, J., Kim, Y., Alexander, G., & Emery, S. (2017). Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009\u20132013. JAMA,\n                           317, 1159\u20131166.","journal-title":"JAMA"},{"key":"41_CR59","doi-asserted-by":"publisher","first-page":"i4608","DOI":"10.1136\/bmj.i4608","volume":"354","author":"J Lenzer","year":"2016","unstructured":"Lenzer, J. (2016). Two years of sunshine: has openness about payments reduced industry influence in healthcare? BMJ,\n                           354, i4608.","journal-title":"BMJ"},{"key":"41_CR60","doi-asserted-by":"publisher","first-page":"e106599","DOI":"10.1371\/journal.pone.0106599","volume":"9","author":"T Leonardo Alves","year":"2014","unstructured":"Leonardo Alves, T., de Freitas, A., van Eijk, M., & Mantel-Teeuwisse, A. (2014). Compliance of disease awareness campaigns in printed Dutch media with national and international regulatory guidelines. PLoS One,\n                           9, e106599. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0106599\n                    \n                  .","journal-title":"PLoS One"},{"key":"41_CR61","unstructured":"Leslie, C. (2015, September 15). Relationship between MDs and pharma changing. Medical Post, p. 45."},{"key":"41_CR62","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1744-8603-8-24","volume":"8","author":"J Lexchin","year":"2012","unstructured":"Lexchin, J. (2012). Models for financing the regulation of pharmaceutical promotion. Globalization and Health,\n                           8, 24.","journal-title":"Globalization and Health"},{"issue":"3","key":"41_CR64","first-page":"1","volume":"13","author":"J Mack","year":"2014","unstructured":"Mack, J. (2014a). The virtual Pharmac sales rep: ensuring the survival of a venerable species. Pharma Marketing News,\n                           13(3), 1\u20133.","journal-title":"Pharma Marketing News"},{"issue":"5","key":"41_CR63","first-page":"1","volume":"13","author":"J Mack","year":"2014","unstructured":"Mack, J. (2014b). Pharma promotional spending in 2013. Pharma Marketing News,\n                           13(5), 1\u20136.","journal-title":"Pharma Marketing News"},{"key":"41_CR65","volume-title":"Medicines out of control? Antidepressants and the conspiracy of goodwill","author":"C Medawar","year":"2004","unstructured":"Medawar, C., & Hardon, A. (2004). Medicines out of control? Antidepressants and the conspiracy of goodwill. The Netherlands: Aksant."},{"key":"41_CR66","doi-asserted-by":"crossref","unstructured":"Medicines Australia code of conduct breaches (2008). Australian Prescriber, 31, 162\u2013163.","DOI":"10.18773\/austprescr.2008.090"},{"key":"41_CR67","unstructured":"Merck Frosst June 17. (1996). Direct-to-consumer advertising of prescription pharmaceuticals. A Merck Frosst position paper on how to use comprehensive patient information to deliver improved, cost-effective health outcomes. Submission to Health Canada consultation on direct-to-consumer advertising of prescription drugs. Ottawa."},{"key":"41_CR68","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.annemergmed.2007.12.009","volume":"51","author":"W Millard","year":"2008","unstructured":"Millard, W. (2008). Dispatch from the pharmasphere: an industry\u2019s fault lines on display. Annals of Emergency Medicine,\n                           51, 175\u2013180.","journal-title":"Annals of Emergency Medicine"},{"key":"41_CR69","volume-title":"Direct-to-consumer advertising of prescription drugs in Canada: What are the public health implications?","author":"B Mintzes","year":"2006","unstructured":"Mintzes, B. (2006). Direct-to-consumer advertising of prescription drugs in Canada: What are the public health implications?. Toronto: Health Council of Canada."},{"key":"41_CR70","doi-asserted-by":"publisher","first-page":"a985","DOI":"10.1136\/bmj.a985","volume":"337","author":"B Mintzes","year":"2008","unstructured":"Mintzes, B. (2008). Direct to consumer advertising of prescription drugs. BMJ,\n                           337, a985.","journal-title":"BMJ"},{"key":"41_CR71","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev-publhealth-031811-124540","volume":"33","author":"B Mintzes","year":"2012","unstructured":"Mintzes, B. (2012). Advertising of prescription-only medicines to the public: does evidence of benefit counterbalance harm? Annual Review of Public Health,\n                           33, 259\u2013277.","journal-title":"Annual Review of Public Health"},{"key":"41_CR72","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1007\/s11606-013-2411-7","volume":"28","author":"B Mintzes","year":"2013","unstructured":"Mintzes, B., Lexchin, J., Sutherland, J., Beaulieu, M.-D., Wilkes, M., Durrieu, G., et al. (2013). Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States. Journal of General Internal Medicine,\n                           28, 1368\u20131375.","journal-title":"Journal of General Internal Medicine"},{"key":"41_CR73","volume-title":"Understanding and responding to pharmaceutical promotion: a practical guide","year":"2010","unstructured":"Mintzes, B., Mangin, D., & Hayes, L. (Eds.). (2010). Understanding and responding to pharmaceutical promotion: a practical guide. Amsterdam and Geneva: Health Action International and World Health Organization."},{"key":"41_CR74","unstructured":"Morelle, A., Bensadon, A.-C., & Marie France, M. (2011). Enqu\u00eate sur le MEDIATOR. \n                    http:\/\/www.igas.gouv.fr\/spip.php?article162\n                    \n                  . Accessed May 18, 2017."},{"key":"41_CR75","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/fampra\/cmi074","volume":"22","author":"P Muijrers","year":"2005","unstructured":"Muijrers, P., Grol, R., Sijbrandij, J., Janknegt, R., & Knottnerus, J. (2005). Differences in prescribing between GPs: Impact of the cooperation with pharmacists and impact of visits from pharmaceutical industry representatives. Family Practice,\n                           22, 624\u2013630.","journal-title":"Family Practice"},{"key":"41_CR76","volume-title":"Making medicines affordable: A national imperative","author":"National Academies of Sciences, Engineering, and Medicine","year":"2017","unstructured":"National Academies of Sciences, Engineering, and Medicine. (2017). Making medicines affordable: A national imperative. Washington, DC: The National Academies Press."},{"key":"41_CR77","unstructured":"Norris, P., Herxheimer, A., Lexchin, J., & Mansfield, P. (2005). Drug promotion: What we know, what we have yet to learn. In W. H. O. and Health Action International (Ed.). Geneva."},{"key":"41_CR78","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJM200007273430417","volume":"343","author":"J Norton","year":"2000","unstructured":"Norton, J. (2000). Is academic medicine for sale? New England Journal of Medicine,\n                           343, 508.","journal-title":"New England Journal of Medicine"},{"key":"41_CR79","unstructured":"Nuland, S., van Eijk, M., & van Brakel, R. (2009). Informatieaanbod op internet (Report commissioned by the Dutch Health Inspectorate). Gezonde scepsis, 96."},{"key":"41_CR80","doi-asserted-by":"publisher","first-page":"e6350","DOI":"10.1371\/journal.pone.0006350","volume":"4","author":"N Othman","year":"2009","unstructured":"Othman, N., Vitry, A., & Roughead, E. (2009). Quality of pharmaceutical advertisements in medical journals: A systematic review. PLoS One,\n                           4, e6350.","journal-title":"PLoS One"},{"key":"41_CR81","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/1471-2458-10-294","volume":"10","author":"N Othman","year":"2010","unstructured":"Othman, N., Vitry, A., & Roughead, E. (2010). Quality of claims, references and the presentation of risk results in medical journal advertising: A comparative study in Australia, Malaysia and the United States. BMC Public Health,\n                           10, 294.","journal-title":"BMC Public Health"},{"key":"41_CR82","doi-asserted-by":"publisher","first-page":"e0155474","DOI":"10.1371\/journal.pone.0155474","volume":"11","author":"R Perlis","year":"2016","unstructured":"Perlis, R., & Perlis, C. (2016). Physician payments from industry are associated with greater. PLoS One,\n                           11, e0155474.","journal-title":"PLoS One"},{"key":"41_CR83","unstructured":"Pharma brands earmark $38 million for thought leaders. (2006). \n                    http:\/\/www.prnewswire.com\/news-releases\/pharma-brands-earmark-38-million-for-thought-leaders-53883072.html\n                    \n                  . Accessed April 14, 2015."},{"key":"41_CR84","unstructured":"Pharmaceutical Adverising Advisory Board (2013). Code of advertising acceptance. \n                    http:\/\/www.paab.ca\/paab-code.htm\n                    \n                  . Accessed September 13, 2014."},{"key":"41_CR85","unstructured":"Pharmaceutical Research and Manufacturers of America (2008). Code of interactions with health professionals. Washington, DC."},{"key":"41_CR86","first-page":"383","volume":"26","author":"Prescrire Editorial Staff","year":"2006","unstructured":"Prescrire Editorial Staff. (2006). 15 ans d\u2019observation et un constat: rien \u00e0 attendre de la visite m\u00e9dicale pour mieux soigner. La revue Prescrire,\n                           26, 383\u2013389.","journal-title":"La revue Prescrire"},{"key":"41_CR87","first-page":"782-781","volume":"27","author":"Prescrire Editorial Staff","year":"2007","unstructured":"Prescrire Editorial Staff. (2007). Observance des traitements: Pas si simple. La revue Prescrire,\n                           27, 782-781\u2013782-784.","journal-title":"La revue Prescrire"},{"key":"41_CR88","first-page":"136","volume":"25","author":"Prescrire Editorial Staff","year":"2016","unstructured":"Prescrire Editorial Staff. (2016). New drugs, new indications in 2015: Little progress, and threats to access to quality Healthcare for all. Prescrire International,\n                           25, 136\u2013139.","journal-title":"Prescrire International"},{"key":"41_CR89","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/fampra\/20.1.61","volume":"20","author":"H Prosser","year":"2003","unstructured":"Prosser, H., Almond, S., & Walley, T. (2003). Influences on GPs\u2019 decision to prescribe new drugs-the importance of who says what. Family Practice,\n                           20, 61\u201368.","journal-title":"Family Practice"},{"key":"41_CR90","volume-title":"Self-regulation of drug promotion. A cross-sectional analysis of pharmaceutical marketing codes and the WHO Ethical Criteria for medicinal drug promotion","author":"M Putzeist","year":"2007","unstructured":"Putzeist, M. (2007). Self-regulation of drug promotion. A cross-sectional analysis of pharmaceutical marketing codes and the WHO Ethical Criteria for medicinal drug promotion. Utrecht: Utrecht University."},{"key":"41_CR91","volume-title":"Effective drug regulation: A multicountry study","author":"S Ratanawijitrasin","year":"2002","unstructured":"Ratanawijitrasin, S., & Wondemagegnehu, E. (2002). Effective drug regulation: A multicountry study. Geneva: World Health Organization."},{"key":"41_CR92","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.socscimed.2007.07.027","volume":"66","author":"J Read","year":"2008","unstructured":"Read, J. (2008). Schizophrenia, drug companies and the internet. Social Science and Medicine,\n                           66, 99\u2013109.","journal-title":"Social Science and Medicine"},{"key":"41_CR93","unstructured":"R\u00e9publique Fran\u00e7aise. (2002). Loi n\u00b02002\u2013303 du 4 mars 2002 relative aux droits des malades et \u00e0 la qualit\u00e9 du syst\u00e8me de sant\u00e9, Article L4113-13 du Code de la Sant\u00e9 publique fran\u00e7ais. \n                    http:\/\/www.legifrance.gouv.fr\/affichCodeArticle.do?idArticle=LEGIARTI000006688689&cidTexte=LEGITEXT000006072665&dateTexte=20080614&fastPos=1&fastReqId=270241154&oldAction=rechCodeArticle\n                    \n                  . Accessed May 18 2017."},{"key":"41_CR94","doi-asserted-by":"publisher","first-page":"e1000128","DOI":"10.1371\/journal.pmed.1000128","volume":"6","author":"J Robertson","year":"2009","unstructured":"Robertson, J., Moynihan, R., Walkom, E., Bero, L., & Henry, D. (2009). Mandatory disclosure of pharmaceutical industry-funded events for health professionals. PLoS Medicine,\n                           6, e1000128.","journal-title":"PLoS Medicine"},{"key":"41_CR95","unstructured":"Rocci, R. (2009). Brazil. In International comparative legal guide to: pharmaceutical advertising 2009. London: Global Legal Group."},{"key":"41_CR96","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2105\/AJPH.2010.300027","volume":"101","author":"S Rothman","year":"2011","unstructured":"Rothman, S., Raveis, V., Friedman, A., & Rothman, D. (2011). Health advocacy organizations and the pharmaceutical industry: An analysis of disclosure practices. American Journal of Public Health,\n                           101, 602\u2013609.","journal-title":"American Journal of Public Health"},{"key":"41_CR97","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2190\/B81X-4A53-TY5M-C2HR","volume":"28","author":"E Roughead","year":"1998","unstructured":"Roughead, E., Gilbert, A., & Harvey, K. (1998). Self-regulatory codes of conduct: are they effective in controlling pharmaceutical representatives\u2019 presentations to general medical practitioners? International Journal of Health Services,\n                           28, 269\u2013279.","journal-title":"International Journal of Health Services"},{"key":"41_CR98","unstructured":"Rout, M. (2009, April 1). Vioxx maker Merck and Co. drew up doctors hit list. The Australian."},{"key":"41_CR99","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/jlme.12076","volume":"41","author":"S Sah","year":"2013","unstructured":"Sah, S., & Fugh-Berman, A. (2013). Physicians under the influence: social psychology and industry marketing strategies. Journal of Law, Medicine & Ethics,\n                           41, 665\u2013672.","journal-title":"Journal of Law, Medicine & Ethics"},{"key":"41_CR100","unstructured":"Santos, A. (2017). The sun shines on Europe: transparency of financial relationships in the healthcare sector. \n                    http:\/\/haiweb.org\/wp-content\/uploads\/2017\/03\/Sunshine-Act.pdf\n                    \n                  . Accessed July 11, 2017."},{"key":"41_CR101","unstructured":"Savas, B., Karahan, \u00d6., Saka, R., Thomson, S., & Mossialos, E. (2002). Health care systems in transition: Turkey. Copenhagen."},{"key":"41_CR102","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3109\/10401230109148963","volume":"13","author":"T Schwartz","year":"2001","unstructured":"Schwartz, T., Kuhles, D. N., Wade, M., & Masand, P. (2001). New admitted psychiatric patient prescriptions and pharmaceutical sales visits. Annals of Clinical Psychiatry,\n                           13, 159\u2013162.","journal-title":"Annals of Clinical Psychiatry"},{"key":"41_CR103","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1369-7625.2006.00411.x","volume":"10","author":"S Semin","year":"2007","unstructured":"Semin, S., Aras, \u00c5., & Guldal, D. (2007). Direct-to-consumer advertising of pharmaceuticals: developed countries experience and Turkey. Health Expectations,\n                           10, 4\u201315.","journal-title":"Health Expectations"},{"key":"41_CR104","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1093\/ajhp\/61.24.2678","volume":"61","author":"N Sibanda","year":"2004","unstructured":"Sibanda, N., Gavaza, P., Maponga, C., & Mugore, L. (2004). Pharmaceutical manufacturers\u2019 compliance with drug advertisement regulations in Zimbabwe. American Journal of Health System Pharmacy,\n                           61, 2678\u20132681.","journal-title":"American Journal of Health System Pharmacy"},{"key":"41_CR105","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1503\/cmaj.150032","volume":"187","author":"S Sismondo","year":"2015","unstructured":"Sismondo, S. (2015). How to make opinion leaders and influence people. CMAJ,\n                           187, 759\u2013760.","journal-title":"CMAJ"},{"key":"41_CR106","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1057\/biosoc.2015.32","volume":"11","author":"S Sismondo","year":"2013","unstructured":"Sismondo, S., & Chloubova, Z. (2013). \u201cYou\u2019re not just a paid monkey reading slides:\u201d How key opinion leaders explain and justify their work. BioSocieties,\n                           11, 199\u2013219.","journal-title":"BioSocieties"},{"key":"41_CR107","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/fampra\/cmp010","volume":"26","author":"J Sondergaard","year":"2009","unstructured":"Sondergaard, J., Vach, K., Kragstrup, J., & Andersen, M. (2009). Impact of pharmaceutical representative visits on GPs\u2019 drug preferences. Family Practice,\n                           26, 204\u2013209.","journal-title":"Family Practice"},{"key":"41_CR108","doi-asserted-by":"publisher","first-page":"e1000352","DOI":"10.1371\/journal.pmed.1000352","volume":"7","author":"G Spurling","year":"2010","unstructured":"Spurling, G., Mansfield, P. R., Montgomery, B., Lexchin, J., Doust, J., Othman, N., et al. (2010). Information from pharmaceutical companies and the quality, quantity, and cost of physicians\u2019 prescribing: a systematic review. PLoS Medicine,\n                           7, e1000352.","journal-title":"PLoS Medicine"},{"key":"41_CR109","unstructured":"Stanford University. (2006). Policy and guidelines for interactins between the Stanford University School of Medicine, the Stanford Hospital and Clinics and Lucile Packard Children\u2019s Hospital with the pharmaceutical, biotech, medical device and hospital and research equipment and supplies industries (\u201cIndustry\u201d). (Revised 2009 ed.). Palo Alto."},{"key":"41_CR110","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1056\/NEJMp0805309","volume":"359","author":"R Steinbrook","year":"2007","unstructured":"Steinbrook, R. (2007). Disclosure of industry payments to physicians. New England Journal of Medicine,\n                           359, 559\u2013561.","journal-title":"New England Journal of Medicine"},{"key":"41_CR111","doi-asserted-by":"publisher","first-page":"284","DOI":"10.7326\/0003-4819-145-4-200608150-00008","volume":"145","author":"M Steinman","year":"2006","unstructured":"Steinman, M., Bero, L., Chren, M., & Landefeld, C. (2006). Narrative review: The promotion of gabapentin: an analysis of internal industry documents. Annals of Internal Medicine,\n                           145, 284\u2013293.","journal-title":"Annals of Internal Medicine"},{"key":"41_CR112","unstructured":"Tigas, M., & Ornstein, C. (2016). We\u2019ve updated Dollars for Docs. Here\u2019s what\u2019s new. \n                    https:\/\/www.propublica.org\/article\/updated-dollars-for-docs-heres-whats-new\n                    \n                  . Accessed July 7, 2017."},{"key":"41_CR113","unstructured":"Total unaudited and audited global pharmaceutical market 2005\u20132014 (2015). \n                    http:\/\/www.imshealth.com\/files\/web\/Corporate\/News\/Top-Line\n                    \n                   Market Data\/2014\/World figures\u00a02014.pdf. Accessed May 15, 2017."},{"key":"41_CR114","first-page":"485","volume":"328","author":"A Tuffs","year":"2004","unstructured":"Tuffs, A. (2004). Only 6% of drug advertising material is supported by evidence. BMJ,\n                           328, 485.","journal-title":"BMJ"},{"key":"41_CR115","unstructured":"United States Government Accountability Office (2006). Prescription drugs\u2014Improvements needed in FDA\u2019s oversight of direct-to-consumer advertising. Washington, DC."},{"key":"41_CR116","unstructured":"Vacca, C. Entender la publicidad y promoci\u00f3n farmac\u00e9utica: experiencias de docencia y investigaci\u00f3n en Am\u00e9rica Latina. In Porto Alegre Congress, Brazil, 2010. FEFAS Magazine."},{"key":"41_CR117","unstructured":"Vacca, C., Vargas, C., & Ca\u00f1as, M. (2009). Regulaci\u00f3n de la publicidad y promoci\u00f3n farmac\u00e9utica. Paper presented at the XV reuni\u00f3n del DURG-LA, Panam\u00e1, September."},{"key":"41_CR118","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.schres.2005.02.001","volume":"77","author":"H Verdoux","year":"2005","unstructured":"Verdoux, H., Cougnard, A., Grolleau, S., & Begaud, B. (2005). Impact of visits from pharmaceutical company representatives on antipsychotic prescription in primary care. Schizophrenia Research,\n                           77, 107\u2013109.","journal-title":"Schizophrenia Research"},{"key":"41_CR119","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/ewjm.174.6.391","volume":"174","author":"V Vlassov","year":"2001","unstructured":"Vlassov, V., Mansfield, P., Lexchin, J., & Vlassova, A. (2001). Do drug advertisements in Russian medical journals provide essential information for safe prescribing? Western Journal of Medicine,\n                           174, 391\u2013394.","journal-title":"Western Journal of Medicine"},{"key":"41_CR120","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1056\/NEJMp058136","volume":"352","author":"H Waxman","year":"2005","unstructured":"Waxman, H. (2005). The lessons of Vioxx-drug safety and sales. New England Journal of Medicine,\n                           352, 2576\u20132578.","journal-title":"New England Journal of Medicine"},{"key":"41_CR121","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1001\/jama.283.3.373","volume":"283","author":"A Wazana","year":"2000","unstructured":"Wazana, A. (2000). Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA,\n                           283, 373\u2013380.","journal-title":"JAMA"},{"key":"41_CR122","doi-asserted-by":"publisher","first-page":"e0156795","DOI":"10.1371\/journal.pone.0156795","volume":"11","author":"B Workneh","year":"2016","unstructured":"Workneh, B., Gebrehiwot, M., Bayo, T., GIdey, M., Belay, Y., Tesfaye, D., et al. (2016). Influence of medical representatives on prescribing practices in Mekelle, Northern Ethiopia. PLoS One,\n                           11, e0156795.","journal-title":"PLoS One"},{"key":"41_CR123","volume-title":"Ethical criteria for medicinal drug promotion","author":"World Health Organization","year":"1988","unstructured":"World Health Organization. (1988). Ethical criteria for medicinal drug promotion. Geneva: World Health Organization."},{"key":"41_CR124","volume-title":"Country pharmaceutical situations: Fact book on WHO level 1 indicators 2007","author":"World Health Organization","year":"2007","unstructured":"World Health Organization. (2007). Country pharmaceutical situations: Fact book on WHO level 1 indicators 2007. Geneva: World Health Organization."},{"key":"41_CR125","volume-title":"Clinical pharmacological evaluation in drug control","author":"World Health Organization Europe","year":"1993","unstructured":"World Health Organization Europe. (1993). Clinical pharmacological evaluation in drug control. Copenhagen: WHO Europe."},{"key":"41_CR126","first-page":"105","volume":"5","author":"L Wzorek","year":"2007","unstructured":"Wzorek, L., Correr, C., Badaro Trindade, A., & Pontarolo, R. (2007). Analysis of medicine advertisement produced in Brazil. Pharmacy Practice,\n                           5, 105\u2013108.","journal-title":"Pharmacy Practice"},{"key":"41_CR127","doi-asserted-by":"publisher","first-page":"e1001785","DOI":"10.1371\/journal.pmed.1001785","volume":"12","author":"A Zetterqvist","year":"2015","unstructured":"Zetterqvist, A., Merlo, J., & Mulinari, S. (2015). Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004\u20132012: A quantitative and qualitative study of pharmaceutical industry self-regulation. PLoS Medicine,\n                           12, e1001785.","journal-title":"PLoS Medicine"},{"key":"41_CR128","doi-asserted-by":"publisher","first-page":"e62609","DOI":"10.1371\/journal.pone.0062609","volume":"8","author":"A Zetterqvist","year":"2013","unstructured":"Zetterqvist, A., & Mulinari, S. (2013). Misleading advertising for antidepressants in Sweden: a failure of pharmaceutical industry self-regulation. PLoS One,\n                           8, e62609.","journal-title":"PLoS One"},{"key":"41_CR129","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1001\/jama.1995.03520400066047","volume":"273","author":"M Ziegler","year":"1995","unstructured":"Ziegler, M., Lew, P., & Singer, B. (1995). The accuracy of drug information from pharmaceutical sales representatives. JAMA,\n                           273, 1296\u20131298.","journal-title":"JAMA"}],"container-title":["Science and Engineering Ethics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11948-018-0041-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11948-018-0041-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11948-018-0041-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T11:11:20Z","timestamp":1563793880000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11948-018-0041-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,2]]},"references-count":129,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["41"],"URL":"https:\/\/doi.org\/10.1007\/s11948-018-0041-5","relation":{},"ISSN":["1353-3452","1471-5546"],"issn-type":[{"value":"1353-3452","type":"print"},{"value":"1471-5546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,2]]},"assertion":[{"value":"4 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Teresa Alves has no conflicts to declare. In 2015\u20132017 Joel Lexchin received payment from two non-profit organizations for being a consultant on a project looking at indication based prescribing and a second looking at which drugs should be distributed free of charge by general practitioners. In 2015 he received payment from a for-profit organization for being on a panel that discussed expanding drug insurance in Canada. He is on the Foundation Board of Health Action International. Barbara Mintzes has acted as an expert witness on behalf of plaintiffs in Canadian class action suits on hormone replacement therapy and breast cancer and cardiovascular risks of testosterone. She has no additional conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}